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Abstract 
Background: Proteostasis is defined by the orchestrated control of anabolic and catabolic protein pathways. Disrup-
tion of proteostasis results in cell stress and adaptation to proteostasis imbalance is mediated by adaptive pathways 
such as the Heat Shock Response (including heat-shock proteins) or the unfolded protein response (UPR). The BCR-
ABL1 kinase (Philadelphia chromosome) is the hallmark of chronic myeloid leukemia (CML) and defines a historically 
poor subset in acute lymphoblastic leukemia (Ph+ ALL). We previously demonstrated the importance of the UPR and 
particularly of the IRE1/XBP1 signaling axis in Ph+ ALL, while others demonstrated the therapeutic relevance of HSP70 
in ALL. In this regard, HSP70 is regulated by smaller HSP40 s, whose function is so far poorly characterized.
Results: Herein, we characterize the expression of HSP40 s in Ph+ ALL and CML. We show that these genes are not 
regulated in a pan-class manner and identify a homologous gene pair, namely Auxilin-1 (DNAJC6) and Auxilin-2 (GAK) 
with a unique expression profile. Overexpression of Auxilin-2, the ubiquitously expressed homologue of Auxilin-1 cor-
related with superior clinical outcome in ALL and was tightly linked to both IRE1 RNase and BCR-ABL1 kinase activities.
Conclusions: Our findings suggest that HSP40 gens are uniquely regulated and provide a rationale for further stud-
ies between BCR-ABL1/IRE1-based therapies in combination with HSP40 inhibitors, thus opening potentially novel 
therapeutic avenues.
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Findings
Control of protein homeostasis (proteostasis) is an 
essential driver of cell survival. In certain hematologi-
cal malignancies such as multiple myeloma, the concept 
of disrupting proteostasis by weakening cancer cells’ 
adaptation to oncogene-induced increased metabolic 
demand and/or to challenging microenvironment has 
shown clinical success [1]. Under challenging conditions, 
proteostasis maintenance is achieved through the activa-
tion of selective adaptive machineries such as the heat 
shock response (HSR) or the unfolded protein response 
(UPR) [2, 3]. The HSR is mainly mediated by Heat Shock 
Factor-1 (HSF1) which is responsible for the induc-
tion of the heat shock proteins (HSPs), that were ini-
tially classified based on their molecular weight [4, 5] 
and are generally regulated by proteotoxic stress [6, 7]. 
For instance, the HSP40 (DNAJ) family of proteins is 
important for protein translation, folding, translocation 
and degradation, mainly by modulating HSP70 ATPase 
activity. While the role of HSP70 is well characterized, 
that of HSP40 proteins, specifically in hematological 
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malignancies remains unclear [8]. Moreover, we have 
recently identified the IRE1/XBP1 axis of the UPR as an 
important survival cue in B-ALL [2, 9]. The IRE1/XBP1 
axis is known to control the expression of several HSP40 
family members [10], which suggests potential functional 
links between HSR and UPR.
To test the potential interplay between those two adap-
tive pathways in leukemia, we studied the expression of 
24 HSP40 members in Ph+ ALL and CML. When com-
paring gene expression of CML patients in chronic phase 
(CP) with terminal blast crisis (BC), HSP40 family mem-
bers showed differential expression. Among the studied 
genes, two members, Auxilin-1 and -2 showed a rather 
unexpected expression profile. Whereas Auxilin-1 was 
highly expressed in BC-CML patients, Auxilin-2 expres-
sion was high in CP-CML and low in BC-CML patients 
(Fig. 1a). In addition, the expression of Auxilins in CML 
patients in all three phases (CP-CML, accelerated phase, 
BC-CML and after remission of BC-CML patients) 
revealed that Auxilin-2 decreased, while Auxilin-1 
increased across disease progression of CML patients 
(Fig.  1b). To discriminate, if HSP40 expression profile 
was CML specific or related to the BCR-ABL1 kinase, 
we next studied the expression of the aforementioned 
genes in Ph+ ALL patient samples. HSP40 family mem-
bers were similarly differentially expressed in Ph+ ALL 
patients compared to CD19+ B-cells from healthy donors 
(Additional file  1: Figure  S1a). Interestingly in Ph+ ALL 
patients, the expression of Auxilin-1 was upregulated, 
while that of Auxilin-2 was again downregulated also 
in other ALL subsets when compared to CD19+ B-cells 
from healthy donors (Fig.  1c). We therefore focused on 
both Auxilins as they showed the most consistent and 
opposite expression pattern in ALL and CML patients 
(Additional file 1: Figure S1b).
Auxilin-1 is considered as the neuron-specific homo-
logue of Auxilin-2 [11] with many overlapping func-
tions, and genetic loss of Auxilin-1 causes upregulation 
of Auxilin-2 [11]. Since one caveat in gene-expression 
approaches is that a probe-set only detects changes 
between two conditions, even if the overall expression 
is marginal, we hypothesized that (a) while Auxilin-1 
expression might be increased in comparison to pre-B 
cells, the overall expression might be negligible in base-
line due to its neuron-specificity and (b) Auxilin-1 upreg-
ulation could cause a compensatory downregulation of 
Auxilin-2, thus biasing our studies. Our hypothesis was 
supported by the fact that mRNA levels of Auxilin-1 were 
low, while that of Auxilin-2 were detectable in primary 
cases of myeloproliferative neoplasms (MPNs), B-ALL 
and B cell Non-Hodgkin Lymphoma (B-NHL) and also 
established leukemia cell lines (Fig.  1d, e, Additional 
file  3: Table  S1). These primary cases (Additional file  3: 
Table S1) were obtained in compliance with the institu-
tional review board of the University of Aachen, ethical 
vote number EK 206/09. The potential upregulation of 
Auxilin-1 outside the nervous system is supported by its 
upregulation in hepatocellular carcinoma patients [12] 
leading to enhanced HCC proliferation and invasion, 
and suggesting neuron-independent and oncogenic func-
tions. Following this notion, while Auxilin-1 expression 
was very low in baseline, treatment of Ph+ leukemia cell 
lines with the ER stresser Thapsigargin caused significant 
upregulation of both Auxilin-1 and -2 (Additional file 2: 
Figure  S2c, d) suggesting that Auxilin-1 can be upregu-
lated outside the nervous system. A similar pattern of 
regulation was previously observed for instance for the 
oncogene BCL6 which is non-detectable at baseline but 
can strikingly be upregulated upon Imatinib (IM) treat-
ment emitting its oncogenic function [13, 14] by allowing 
leukemia cells to escape TKI-mediated cell death.
We next studied the clinical relevance of both Auxilin 
genes. In two independent data sets of the ECOG E2993 
clinical trial that included either 36 patients with Ph+ 
ALL [15], or 165 ALL cases [16], we segregated patients 
into two groups based on Auxilin-1 and -2 mRNA lev-
els above or below their median expression value. ALL 
patients within the Auxilin-1Hi or Auxilin-2Low groups 
showed worse overall survival compared to those in the 
Auxilin-1Low or Auxilin-2Hi groups (P = 0.02; Fig. 2a, b). 
This supports the notion that Auxilin expression could 
be used as potential predictor of clinical outcome. A 
multivariate analysis based on the median expression of 
both genes with each other or with XBP1, which we had 
previously shown to be a predictor of poor outcome [9], 
revealed that under all conditions, when patients were 
segregated in the Auxilin-2Hi, Auxilin-1Low (Fig.  2c) or 
XBP1Low groups (Fig. 2d, e), they had a better overall sur-
vival when compared to groups exhibiting Auxilin-2Low, 
Auxilin-1Hi or XBP1Hi expression suggesting that the 
genes are predictors of survival.
The recent finding that Auxilin-2 knockout in MEFs 
does not cause the upregulation of Auxilin-1 suggests 
that the genes might act independently under certain 
conditions [17], even though Auxilin-1 knockout mice 
showed compensatory upregulation Auxilin-2 [11]. Taken 
together, the comparison of the studied HSP40 family 
members in leukemia suggested quite unique regulation 
(Additional file 1: Figure S1b). Since several HSP40 fam-
ily members were upregulated in CML and Ph+ ALL, 
both driven by the BCR-ABL1 oncogene, we wanted 
to further understand if the expression of those genes 
might be linked to BCR-ABL1 kinase activity. We first 
studied their expression in a microarray of BCR-ABL1 
transformed ALL cells treated with the tyrosine kinase 
inhibitor (TKI) Imatinib (Additional file 2 : Figure  S2a). 




Fig. 1 Heat shock protein members are differentially expressed in Ph+ leukemia. Gene expression profiling of CML patient samples in chronic 
phase and blast crisis. Highlighted are two homologues Auxilin-2 and Auxilin-1 (GEO accession number GSE4170) (a). In the same microarray (GEO 
accession number GSE4170) showed in Fig. 1a, CML patients were separated depending on their disease stage and the gene expression of Auxilin-1 
and Auxilin-2 are shown after log2 transformation (b). The expression of Auxilin-1 and Auxilin-2 is shown for different ALL subsets carrying either 
BCR-ABL1, TEL-AML1, MLLr or TCF3-PBX1 lesions compared to CD19+ B-cells from healthy donors (http://www.stjuderesearch.org/site/data/ALL3/) 
(c). The mRNA levels of Auxilin-1 and Auxilin-2 were measured by qRT-PCR in primary cases of different hematological malignancies including ALL, 
Essential Thrombocythemia (ET), Polycythemia Vera (PV) compared to B-cell Non-Hodgkin Lymphoma (B-NHL) (d). Similarly, the mRNA levels of 
Auxilin-1 and Auxilin-2 were measured by qRT-PCR (used primers are shown in Table S2) in ALL and CML cell lines with different oncogenic lesions 
(e)
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Several members which were previously downregulated 
in Ph+ ALL cases (Additional file  1: Figure  S1a) were 
now upregulated upon TKI treatment including Jdd1 
(Dnajc9), Mdg1 (Dnajb9), Tpr2 (Dnajc7), Erdj1 (Dnajc1), 
Mcj (Dnajc15) and Auxilin-2 (Gak), while others, previ-
ously upregulated in Ph+ ALL cases such as Auxilin-1 
(Dnajc6), Nedd7 (Dnaja1), Rdj2 (Dnaja2), Tid1 (Dnaja3) 
and Dnajc16 were downregulated upon TKI treatment 
(Additional file 1: Figure S2a). Due to the very low base-
line expression of Auxilin-1 mRNA levels, we focused 
our studies on Auxilin-2 and verified the upregulation of 
Auxilin-2 mRNA levels in Ph+ ALL and CML cell lines 
treated with either Imatinib, or the 2nd generation TKI, 
Nilotinib (Fig. 2f, Additional file 2: Figure 2b). The differ-
ential regulation of individual HSP40  s upon TKI treat-
ment suggest rather specific than a pan-class function. 
For instance NEDD7 (DNAJA1) which was downregu-
lated by TKI-treatment has been described to be impor-
tant for activation-induced cytidine deaminase (AID) 
function, a known oncogene in ALL [18, 19], whereas 
TKI treatment causes downregulation of AID [20]. Our 
finding might be the missing link between TKI treatment 
and AID downregulation through potential downregula-
tion of NEDD7 (DNAJA1) and thereby negatively affect-
ing AID function. Other important HSP40 members 
included MDG1 (DNAJB9) and TPR2 (DNAJC7), both 
upregulated by TKI-treatment and known to positively 
regulate the tumor suppressor p53 [21, 22]. We had pre-
viously shown that TKI treatment leads to downregula-
tion of XBP1 s, while inhibition of XBP1 s activation by 
pharmacological inhibitors of IRE1 RNase activity caused 
apoptosis in Ph+ ALL cells [9]. As such the IRE1 RNase 
inhibitor MKC-8866 caused upregulation of Auxilin-2 in 
Ph+ ALL and CML cells (Fig. 2g). This suggests that BCR-
ABL1 kinase activity might cause potentially proteostasis 
imbalance leading to activation of the UPR, as previously 
identified by us and downregulation of individual HSP40 
family members, which might hold the key to novel ther-
apeutic approaches targeting the proteostatic network.
Taken together, our study provides for the first time, 
a more comprehensive overview of the expression and 
regulation of this understudied gene family in leukemias 
and more importantly shows that HSP40 family members 
can act as predictors of clinical outcome and are rather 
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Fig. 2 Auxillin-1 and 2 correlate with clinical outcome of ALL patients. In an analysis, ALL patients (ECOG E2993 [15, 16], n = 36, logrank test 
P = 0.02) were segregated into two groups based on high or low mRNA levels in respect to the median mRNA value of the Auxilin-1 and -2 probe-
set and the overall survival (OS) was assessed (a, b). Similarly, in a multivariate analysis; the ALL patients were segregated in two groups, according 
on high or low mRNA levels of Auxilin-1 and -2 (c), XBP1 and Auxilin-1 (d) or XBP1 and Auxilin-2 and overall survival was assessed (e). The patient 
subcohorts are mentioned in the according headlines (a–d). Auxilin-2 mRNA levels were measured by qRT-PCR in Ph+ ALL and CML cell lines (SUP-
B15, TOM-1 and KCL-22) treated with or without the TKI Nilotinib for 16 h (5 µM) (n = 3) (f) and with or without the IRE1 RNase inhibitor MKC-8866 
for 16 h (30 µM MKC-8866) (n = 3) (g)
regulated by the BCR-ABL1 kinase activity specifically 
than in a pan-class manner.
Additional files
Additional file 1: Figure S1. Heat shock protein members are differen-
tially expressed in Ph+ leukemia. Gene expression profiling of Ph+ ALL 
patient samples compared to CD19+ B-cells from healthy donors (http://
www.stjuderesearch.org/site/data/ALL3/) (a). A summary of the different 
expression profiles of the studied HSP40 (DNAJ) family members in this 
study is shown (b).
Additional file 2: Figure S2. Auxilin-2 expression is regulated by IRE-1 
RNase and BCR-ABL1 kinase activity in Ph+ ALLGene expression profiling 
of BCR-ABL1-transformed ALL cells treated with Imatinib 2 μM for 24 h 
(GEO accession numbers GSE20987) (a). Auxilin-2 mRNA levels were 
measured by qRT-PCR in Ph+ ALL and CML cell lines (SUP-B15, TOM-1 and 
KCL-22) treated with or without Imatinib for 16 h (10 μM Imatinib) (n = 3) 
(b). Auxilin-2 (c) and Auxilin-1 (d) mRNA levels were measured by qRT 
-PCR in Ph+ ALL and CML cell lines (SUP-B15, TOM-1 and KCL-22) treated 
with or without ER stresser Thapsigargin for 16 h (100 ng/mL Thapsigargin 
for SUP-B15 and TOM-1 and 200 ng/mL for KCL-22).
Additional file 3: Table S1. Overview of patient-derived samples of 
Ph + ALL and cell lines. Table S2. Sequences of oligonucleotide primers 
used.
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